Phio Pharmaceuticals Corp.

Stage 4 · Declining · week 3

As of Oct 22, 2026, Phio Pharmaceuticals is in Stage 4, the downtrend phase, now in week 3 (since Oct 7, 2026). It closed at $0.87, 59.6% below its 52-week high and below its 200-day average, which is falling.

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. More about the company

$0.87

-2.45% today

$10.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PHIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S4 17w

S4 23w

S4 16w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 30w → S1 8w → S4 7w → S1 2w → S4 17w → S1 2w → S4 23w → S1 11w → S2 5w → S3 12w → S4 16w → S1 10w → S4 14w → S1 5w → S4 2w current

Total tracked: 165 weeks across 15 stage runs.

PHIO among Biotechnology389th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…389	PHIOPhio Pharmaceuticals Corp.	Stage 4 · wk 3	19	−14.4%

vs 52W High

-59.6%

$0.86 lo$2.16 hi

59.6% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 3

1w13w26w

Week 3, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-20.4%

200 DMA: $1.10 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.39x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-14.4%

-16.1%

-29.0%

YTD

-19.9%

-59.0%

Scan Membership

Breakout Watch

Latest: 2020-12-17

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 3 · Vol 0.39x

2026-10-21S4

Wk 3 · Vol 0.71x

2026-10-20S4

Wk 2 · Vol 0.42x

2026-10-19S4

Wk 2 · Vol 0.63x

2026-10-16S4

Wk 2 · Vol 0.64x

2026-10-15S4

Wk 2 · Vol 0.97x

2026-10-14S4

Wk 2 · Vol 0.92x

2026-10-13S4

Wk 1 · Vol 0.48x

2026-10-12S4

Wk 1 · Vol 0.31x

2026-10-09S4

Wk 1 · Vol 0.30x

2026-10-08S4

Wk 1 · Vol 0.45x

2026-10-07S41→4

Wk 1 · Vol 0.63x

Moving averages & range

50 DMA

$1.03

200 DMA

$1.10

52W High

$2.16

52W Low

$0.86

5D Low

$0.87

Resistance levels (recent highs)

20d High

$1.03

60d High

$1.21

120d High

$1.21

250d High

$2.16

Next resistance

+18.0%

to 20d High

ROE

-113.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.8

Phio Pharmaceuticals: quick answers

What stage is Phio Pharmaceuticals in?

As of Oct 22, 2026, Phio Pharmaceuticals (PHIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 7, 2026 and is in week 3. What the four stages mean

Is Phio Pharmaceuticals in an uptrend?

No. Phio Pharmaceuticals is in a Stage 4 downtrend. It trades 20.4% below its 200-day average, which is falling.

How far is Phio Pharmaceuticals from its 52-week high?

Phio Pharmaceuticals closed at $0.87 on Oct 22, 2026, 59.6% below its 52-week high of $2.16. Its 52-week low is $0.86.

How has Phio Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Phio Pharmaceuticals is down 59.0% over the past year and down 19.9% so far in 2026.

Which sector and industry is Phio Pharmaceuticals in?

Phio Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.